Agios Pharmaceuticals Inc
SWB:8AP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Agios Pharmaceuticals Inc (8AP) under the Base Case is 39.38 EUR per share.
Compared with the current market price of 27 EUR, the stock appears
Undervalued by 31% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Agios Pharmaceuticals Does
Agios Pharmaceuticals is a biotech company that develops medicines for rare blood disorders. Its main approved drug is Pyrukynd, a pill used to treat certain inherited anemia conditions by helping red blood cells make energy more efficiently. The company also keeps working on other drug candidates in rare hematology, using the same idea of targeting cell metabolism.
- Headquarters
- United States of America US
- Employees
- 539
- IPO date
- Jul 24, 2013
Balance Sheet
Recent Events
Latest Earnings Call
Agios paired record third-quarter product revenue with a launch-ready sickle cell franchise, while an FDA major amendment moved the PDUFA goal date to February 1, 2027.
Open the earnings call- EPS
- −$1.09
- Expected
- −$1.32
- Surprise
- +17.4%
- Stock, day of the call
- −9.9%
Agios Pharmaceuticals insiders are selling within their usual range
Past 12 months
Continue 8AP Research
Decided on Agios Pharmaceuticals? Get an email when 8AP reaches the price you’d buy at. Free with an account.
Other Agios Pharmaceuticals listings
What is the Intrinsic Value of one 8AP stock?
The intrinsic value for
Agios Pharmaceuticals Inc (8AP) under the Base Case is 39.38 EUR.
Is 8AP stock undervalued or overvalued?
Compared with the current market price of 27 EUR, the stock appears Undervalued by 31% .